Action Bitwise Avalanch - BAVA

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

( - )

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has...

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government...

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and...

Bavarian Nordic's IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

KVISTGAARD, Denmark, May 31, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that the Committee for Medicinal Products...

Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US

KVISTGAARD, Denmark, May 29, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that it has established a sponsored Level 1...

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

MOUNTAIN VIEW, Calif., May 29, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic (OMX:BAVA) announced today that promising data from a Phase 2 trial of...

Bavarian Nordic Announces Presentation of PROSTVAC(R) at the 2013 ASCO Annual Meeting

KVISTGAARD, Denmark, May 27, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) announced today that a new planned trial of PROSTVAC® in...

Bavarian Nordic Reports First Quarter 2013 Results

KVISTGAARD, Denmark, May 16, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) today publishes its first quarter 2013 results. Revenue for...

Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliv

KVISTGAARD, Denmark, April 16, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) announced today that BARDA (Biomedical Advanced Research...

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

KVISTGAARD, Denmark, April 8, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) today announced that the Company plans to conduct an...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

BAVA - Frequently Asked Questions (FAQ)

What is the current Common Shares of Beneficial Interest of Bitwise Avalanche share price?

The current share price of Common Shares of Beneficial Interest of Bitwise Avalanche is US$ 0,00

What is the 1 year trading range for Common Shares of Beneficial Interest of Bitwise Avalanche share price?

Common Shares of Beneficial Interest of Bitwise Avalanche has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA)

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

BAVA Dernières nouvelles

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

Bavarian Nordic's IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

Bavarian Nordic Announces Presentation of PROSTVAC(R) at the 2013 ASCO Annual Meeting

Bavarian Nordic Reports First Quarter 2013 Results

Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliv

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

BAVA - Frequently Asked Questions (FAQ)

BAVA Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA)

Common Shares of Beneficial Interest of Bitwise Avalanche (BAVA) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

BAVA Dernières nouvelles

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

Bavarian Nordic's IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

Bavarian Nordic Announces Presentation of PROSTVAC(R) at the 2013 ASCO Annual Meeting

Bavarian Nordic Reports First Quarter 2013 Results

Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliv

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bitwise Launches Spot Avalanche ETP (BAVA); Includes In-House Staking To Maximize Staking Rewards and Oversight

BAVA - Frequently Asked Questions (FAQ)

BAVA Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS